Last updated: August 5, 2026
MULPLETA, the U.S. brand name for lusutrombopag, is a thrombopoietin receptor agonist marketed by Shionogi for adults with chronic liver disease and thrombocytopenia who are scheduled to undergo a procedure. Its commercial value is concentrated in a narrow procedural market rather than chronic platelet management. The product has a differentiated oral dosing profile, but its growth is constrained by limited treatment duration, hospital formulary control, competing platelet-raising agents, and the absence of separately reported product revenue in Shionogi’s public financial disclosures.
What is MULPLETA and what is it approved to treat?
MULPLETA contains lusutrombopag, an orally administered thrombopoietin receptor agonist. The FDA approved it in July 2018 for adults with chronic liver disease and thrombocytopenia scheduled to undergo a procedure. Treatment is administered once daily for seven days, with the procedure generally occurring between Days 9 and 14 after treatment begins.[1]
| Attribute |
MULPLETA |
| Active ingredient |
Lusutrombopag |
| Drug class |
Oral thrombopoietin receptor agonist |
| U.S. sponsor |
Shionogi Inc. |
| U.S. indication |
Thrombocytopenia in adults with chronic liver disease scheduled for a procedure |
| FDA approval |
July 2018 |
| Dosage |
3 mg orally once daily for seven days |
| Primary commercial use |
Avoidance or reduction of platelet transfusion before procedures |
| Administration setting |
Primarily specialty, hospital, and procedural care |
| Biosimilar pathway |
Not applicable; MULPLETA is a small molecule |
MULPLETA increases platelet production by activating the thrombopoietin receptor. It is not approved for routine long-term correction of thrombocytopenia or for emergency treatment of active bleeding. Its label carries warnings concerning portal vein and other thrombotic events, particularly in patients with chronic liver disease.[1]
How large is the MULPLETA market?
MULPLETA addresses a defined but limited patient population: adults with chronic liver disease, clinically significant thrombocytopenia, and an upcoming invasive procedure. The market is driven by the number of eligible procedures, platelet-transfusion practices, payer coverage, and treatment-site protocols.
The addressable market is narrower than the broader thrombocytopenia market for three reasons:
- The drug is used before a scheduled procedure.
- The seven-day regimen limits repeat and chronic use.
- Patients with very high thrombotic risk or other contraindications may not be suitable candidates.
The commercial opportunity is concentrated in hepatology, gastroenterology, interventional radiology, surgery, and transplant-related care. Hospitals and procedural centers often determine whether oral platelet-raising therapy is used instead of platelet transfusion.
The principal value proposition is operational. MULPLETA can reduce or avoid platelet transfusion and may reduce procedure delays associated with arranging blood products. The economic case depends on the cost of transfusion, the procedure’s urgency, local blood-bank capacity, and reimbursement policy.
How does MULPLETA compare with DOPTELET?
DOPTELET, or avatrombopag, is MULPLETA’s closest branded competitor in the U.S. market. Both products are oral thrombopoietin receptor agonists approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
| Factor |
MULPLETA |
DOPTELET |
| Active ingredient |
Lusutrombopag |
Avatrombopag |
| Manufacturer |
Shionogi |
Dova Pharmaceuticals, now within Sobi |
| FDA approval for CLD thrombocytopenia |
2018 |
2018 |
| Treatment schedule |
3 mg daily for seven days |
Dose varies by baseline platelet count; generally five days |
| Platelet assessment |
Less dependent on dose adjustment by baseline count |
Baseline platelet count determines dose |
| Main use |
Planned procedures in chronic liver disease |
Planned procedures in chronic liver disease |
| Competitive distinction |
Simple fixed-dose regimen |
Shorter regimen and dose-based treatment |
| Biosimilar risk |
None |
None |
The competitive decision is usually based on procedure timing, baseline platelet count, payer policy, physician familiarity, contract pricing, and institutional protocols. DOPTELET’s shorter treatment course can be commercially attractive where procedure scheduling is compressed. MULPLETA’s fixed-dose regimen can simplify prescribing and pharmacy operations.
Platelet transfusion remains a substitute, particularly when the procedure is urgent, the patient is admitted, or clinicians prefer immediate correction. Other thrombopoietin receptor agonists, including eltrombopag and romiplostim, are less direct substitutes because their approved uses, dosing patterns, or procedural indications differ.
What is the financial trajectory of MULPLETA?
Shionogi does not generally disclose MULPLETA revenue as a separate public line item in the company’s consolidated financial reporting. The product is included within broader categories of prescription medicines or products, depending on the reporting period and geographic segment.[2]
As a result, a reliable public year-by-year sales series for MULPLETA cannot be established from Shionogi’s standard annual reports alone. The financial trajectory is best assessed through commercial indicators rather than reported product revenue.
| Financial driver |
Effect on MULPLETA |
| U.S. launch in 2018 |
Created a new branded oral option for procedure-related thrombocytopenia |
| DOPTELET competition |
Limited pricing power and increased formulary pressure |
| Narrow indication |
Restricts patient volume and repeat utilization |
| Seven-day course |
Limits cumulative treatment exposure per patient |
| Transfusion avoidance |
Supports value-based adoption in selected institutions |
| Lack of chronic indication |
Reduces recurring prescription volume |
| Specialty distribution |
Concentrates sales through controlled channels and procedural centers |
| Shionogi portfolio strategy |
Makes product-level capital allocation difficult to assess externally |
MULPLETA is more likely to generate stable niche revenue than blockbuster-scale revenue. The product’s economics depend on maintaining access in treatment centers and securing reimbursement for a short, procedure-linked course. Its revenue base is less exposed to daily adherence than chronic medicines but more exposed to procedure volume and hospital purchasing decisions.
When does MULPLETA lose exclusivity?
MULPLETA’s U.S. market exclusivity is determined by several separate rights:
- FDA regulatory exclusivity
- Listed patents in the Orange Book
- Unlisted or non-Orange-Book patent rights
- Pediatric exclusivity, if granted
- Hatch-Waxman litigation and settlement outcomes
The FDA approval in 2018 did not create a long-term biologic-style exclusivity period because lusutrombopag is a small molecule. The product is therefore exposed to ANDA-based generic competition once applicable patent and regulatory barriers have expired.
Public FDA materials establish the approval and labeling history, but an exact generic-entry date cannot be inferred from approval alone. A definitive date requires a current review of the FDA Orange Book, patent certifications filed by ANDA applicants, any Paragraph IV litigation, and settlement terms. The same analysis must distinguish patent expiry from the date on which a generic could actually launch.
What patents protect MULPLETA?
MULPLETA may be protected by composition, pharmaceutical formulation, manufacturing, and method-of-use rights. The commercial relevance of each category differs.
Composition patents
Composition patents generally provide the strongest protection because they cover the active molecule or a defined chemical class. Their value depends on claim scope, validity, terminal disclaimers, patent-term adjustment, and expiration.
Formulation patents
Formulation claims may cover tablet composition, excipients, dissolution, stability, or dosage characteristics. These patents can create additional litigation exposure for an ANDA applicant, but they are often narrower than composition claims and may be easier to design around.
Method-of-use patents
MULPLETA’s procedural indication creates potential method-of-use protection around increasing platelet counts in patients with chronic liver disease before an invasive procedure. An ANDA applicant may use a Paragraph IV certification, a Section viii statement, or labeling strategies that omit patented uses, depending on the scope of the listed claims.
Manufacturing patents
Manufacturing rights can cover intermediates, stereochemistry, crystallization, purification, or production processes. These rights may not block a conventional ANDA if the generic manufacturer can use a non-infringing process, but they can raise supply-chain and technical-development costs.
An accurate current patent table with patent numbers, expiration dates, assignees, and Orange Book status is not established by the FDA approval label or Shionogi’s general public financial reports. Treating an unverified patent number as a MULPLETA blocking patent would create material diligence risk.
Which companies are challenging MULPLETA with generics?
No publicly established, commercially material Paragraph IV challenge to MULPLETA can be confirmed from the core FDA label and Shionogi financial disclosures alone. Generic competition remains a future risk because lusutrombopag is a small molecule and can be pursued through the ANDA pathway.
A generic entrant would need to demonstrate pharmaceutical equivalence and bioequivalence, address any listed patents, and obtain approval for an appropriate label. The most likely challenge sequence would be:
- ANDA filing with Paragraph IV or Section viii certifications.
- Notice to the patent holder.
- Potential Hatch-Waxman litigation.
- A 30-month stay if statutory conditions are met.
- Settlement, licensed entry, or litigation-driven launch.
- Commercial entry after approval and the resolution of enforceable barriers.
What is the FDA and Orange Book status of MULPLETA?
The FDA approved MULPLETA in 2018, and the product remains regulated as an approved small-molecule prescription medicine. FDA labeling identifies the indication, dosing, warnings, and clinical-study results.[1]
Orange Book status is more dynamic than approval status. Patent listings, delistings, expiry calculations, pediatric extensions, and generic applications can change over time. The presence of a patent listing does not establish that the patent will survive litigation. Conversely, the absence of a public litigation record does not eliminate future Paragraph IV risk.
What patent litigation affects MULPLETA?
A material, publicly established MULPLETA patent litigation record is not identified in the core approval materials or Shionogi’s general financial reporting. This does not establish that no patent dispute exists in every jurisdiction. U.S. litigation risk would depend on the patents listed for the reference product and the certifications made by individual ANDA applicants.
The litigation risk is likely to center on:
- Active-ingredient or composition claims
- Procedure-related method-of-use claims
- Formulation claims
- Patent-term calculations
- Carve-out labeling
- Whether a generic launch would induce infringement
What licensing deals affect MULPLETA?
MULPLETA is primarily associated with Shionogi’s development and commercialization platform. No major third-party licensing transaction is required to explain its U.S. commercial position. Shionogi’s public corporate disclosures do not present a separately quantified MULPLETA royalty stream or a major external co-commercialization arrangement comparable to the licensing structures used for some other branded medicines.[2]
This reduces disclosure visibility. It also means that product economics are largely embedded in Shionogi’s consolidated pharmaceutical performance rather than reported as a transparent asset-level income statement.
What generic launch scenarios exist for MULPLETA?
Scenario 1: No near-term generic entry
A generic may not launch if no applicant files an ANDA, if patent protection remains enforceable, or if the market is too small to justify development and litigation costs.
Scenario 2: First generic entry after settlement
A Paragraph IV settlement could establish a future licensed-entry date. This scenario would preserve some branded revenue before entry while creating a defined erosion point.
Scenario 3: At-risk generic launch
An applicant could launch before final patent resolution if it accepts infringement risk. This would create the sharpest exposure to MULPLETA revenue, price, and formulary share.
Scenario 4: Limited substitution
Even after generic approval, substitution may be slower than in large retail markets because use is concentrated in hospitals, specialty pharmacies, and procedure centers. Institutional contracts and physician protocols can delay full conversion.
How strong is the MULPLETA commercial and patent estate?
Commercially, MULPLETA has moderate product differentiation but limited market breadth. Its fixed seven-day regimen and oral administration support adoption, while DOPTELET, platelet transfusion, and procedure-specific clinical practices constrain expansion.
The patent estate cannot be rated definitively without a current, claim-level review of U.S., European, Japanese, and other jurisdictional records. The most important diligence question is whether enforceable composition protection remains in force or whether the remaining barriers are limited to narrower formulation and method-of-use claims.
Geographically, Shionogi’s strongest strategic control is likely in Japan and the United States, where the company has established commercial infrastructure. Europe and other markets depend on country-specific approvals, reimbursement, patent terms, and local competitors.
Key Takeaways
- MULPLETA is lusutrombopag, an oral thrombopoietin receptor agonist approved for adults with chronic liver disease and thrombocytopenia before a scheduled procedure.
- Its market is specialized and procedure-driven, not a broad chronic thrombocytopenia market.
- DOPTELET is the closest branded competitor and offers a shorter, platelet-count-dependent regimen.
- Shionogi does not generally disclose MULPLETA revenue separately, preventing a reliable public product-level sales trajectory.
- The product’s financial outlook depends on procedure volumes, hospital access, reimbursement, transfusion avoidance, and competition from DOPTELET.
- MULPLETA is a small molecule and therefore has future ANDA and Paragraph IV exposure.
- An exact U.S. patent-expiration and generic-entry date is not established by the FDA approval label or Shionogi’s general financial filings.
- The principal commercial risk is not biosimilar substitution. It is conventional generic entry combined with institutional formulary switching.
- The most valuable remaining IP would be enforceable composition protection. Narrower formulation or method-of-use patents would provide less durable protection.
FAQs about MULPLETA exclusivity, pricing, and competition
Is MULPLETA a biologic or a small-molecule drug?
MULPLETA is a small-molecule drug containing lusutrombopag. It is subject to the conventional generic-drug framework rather than the biosimilar pathway.
Can MULPLETA be used for chronic immune thrombocytopenia?
The FDA indication is thrombocytopenia in adults with chronic liver disease who are scheduled for a procedure. It is not approved as a general chronic treatment for immune thrombocytopenia.
What is the main substitute for MULPLETA?
The main branded substitute is DOPTELET, or avatrombopag. Platelet transfusion is the principal procedural alternative.
Does MULPLETA have biosimilar risk?
No. Biosimilars apply to biological products. MULPLETA’s relevant post-exclusivity threat is generic lusutrombopag.
Why are MULPLETA sales difficult to estimate?
Shionogi’s public financial reports generally do not provide a separate MULPLETA revenue line. Sales are embedded in broader product or pharmaceutical categories.
References
-
U.S. Food and Drug Administration. (2018). Mulpleta (lusutrombopag) prescribing information. FDA.
-
Shionogi & Co., Ltd. (2024). Annual report and financial results materials. Shionogi & Co., Ltd.